Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to immunotherapy, focused on engineering a novel class of T cell activators. These therapies are designed to leverage the body's own immune system to fight cancer and other diseases in patients across the United States. The company's innovative Tri-specific T cell activating construct (TriTAC) platform forms the basis of its development pipeline.
| Date | Est. | Actual | |
|---|---|---|---|
| Mar 25, 2024 | -$0.50 | -$5.50 | Miss |
| Nov 13, 2023 | -$3.09 | -$0.46 | Beat |
| Aug 9, 2023 | -$4.30 | $0.30 | Beat |
| May 11, 2023 | -$4.20 | -$3.10 | Beat |
| Mar 27, 2023 | -$4.30 | -$5.50 | Miss |
| Nov 14, 2022 | -$6.00 | -$3.50 | Beat |